MedTrace Logo

Impact of Bone Mineral Density on Fracture Risk Assessment in RA

NCT06718985 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2024-12-05

No results posted yet for this study

Summary

This study investigates whether incorporating bone mineral density (BMD) into FRAX calculations changes fracture risk assessment and influences treatment decisions in rheumatoid arthritis (RA) patients. Analyzing 60 RA patients, FRAX scores for 10-year major osteoporotic and hip fractures were calculated with and without BMD. While no significant differences were found between the two methods, discrepancies in treatment recommendations were identified, particularly for hip fractures. The findings emphasize the importance of combining BMD and FRAX for a more comprehensive fracture risk assessment and informed treatment decision-making in RA patients.

Conditions

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • Istanbul Physical Medicine Rehabilitation Training and Research Hospital

    lead OTHER_GOV

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-04
Primary Completion
2023-04-04
Completion
2023-04-04

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06718985 on ClinicalTrials.gov